Literature DB >> 17072603

Methods developed for SELEX.

Subash Chandra Bose Gopinath1.   

Abstract

SELEX (systematic evolution of ligands by exponential enrichment) is a process that involves the progressive purification from a combinatorial library of nucleic acid ligands with a high affinity for a particular target by repeated rounds of partitioning and amplification. With the development of aptamer technology over the last decade, various modified SELEX processes have arisen that allow various aptamers to be developed against a wide variety of molecules, irrespective of the target size. In the present review, the separation methods used in such SELEX processes are reviewed.

Mesh:

Substances:

Year:  2006        PMID: 17072603     DOI: 10.1007/s00216-006-0826-2

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  82 in total

1.  Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Authors:  Farid Rahimi; Gal Bitan
Journal:  J Vis Exp       Date:  2010-05-13       Impact factor: 1.355

Review 2.  Recent developments in protein and cell-targeted aptamer selection and applications.

Authors:  Jun Liu; Mingxu You; Ying Pu; Huixia Liu; Mao Ye; Weihong Tan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

4.  Micromagnetic selection of aptamers in microfluidic channels.

Authors:  Xinhui Lou; Jiangrong Qian; Yi Xiao; Lisan Viel; Aren E Gerdon; Eric T Lagally; Paul Atzberger; Theodore M Tarasow; Alan J Heeger; H Tom Soh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

5.  In vitro selection with artificial expanded genetic information systems.

Authors:  Kwame Sefah; Zunyi Yang; Kevin M Bradley; Shuichi Hoshika; Elizabeth Jiménez; Liqin Zhang; Guizhi Zhu; Savita Shanker; Fahong Yu; Diane Turek; Weihong Tan; Steven A Benner
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-30       Impact factor: 11.205

6.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

7.  Labelling of live cells using fluorescent aptamers: binding reversal with DNA nucleases.

Authors:  Hideyuki Terazono; Yu Anzai; Mikhail Soloviev; Kenji Yasuda
Journal:  J Nanobiotechnology       Date:  2010-04-13       Impact factor: 10.435

8.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

9.  Reactivity-dependent PCR: direct, solution-phase in vitro selection for bond formation.

Authors:  David J Gorin; Adam S Kamlet; David R Liu
Journal:  J Am Chem Soc       Date:  2009-07-08       Impact factor: 15.419

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.